艾德生物 (300685)

Amoy Diagnostics Co.,Ltd.

ASZ

Tags

Specialized-Sophisticated-Distinctive-Innovative EnterprisesPension FundsInnovative DrugsPharmaceutical ManufacturingBuyback PlansGene ConceptSmart HealthcareWest Coast of the Taiwan StraitHigh-Performing StocksMargin Trading and Securities LendingChiNext 200 IndexChiNext 300 IndexChiNext Blue ChipChiNext Healthcare

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 39153.61
  • Circulating A-Shares(W): 38959.74
  • Earnings Per Share(RMB): 0.6700
  • Net Assets Per Share(RMB): 5.0032
  • Operating Revenue(W RMB): 86563.30
  • Total Profit(W RMB): 30081.74
  • Net Profit Attributable to Parent(W RMB): 26250.59
  • Net Profit Growth Rate(%): 15.50
  • Weighted Return on Equity(%): 13.7900
  • Operating Cash Flow Per Share(RMB): 0.7030
  • Undistributed Profit Per Share(RMB): 3.3879
  • Capital Reserve Per Share(RMB): 0.3118

2. Main Business

The main business covers:

  • Detection reagents, software and supporting instruments
  • Detection services
  • Drug clinical research services

3. Company Basic Information

  • Company Name: Amoy Diagnostics Co., Ltd.
  • Listing Date: 2017-08-02
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 39 Dingshan Road, Haicang District, Xiamen City, Fujian Province, China
  • Website: www.amoydx.com
  • Company Profile: Amoy Limited was jointly established by Xiamen Hengxing and AMOY (invested by the company's actual controller LI-MOU ZHENG (Zheng Limou), the company has been deregistered) on February 21, 2008. On November 23, 2007, Xiamen Hengxing and AMOY signed the "Sino-foreign Equity Joint Venture Contract" and the "Articles of Association of Xiamen Aiming Biotechnology Co., Ltd.", agreeing to establish a Sino-foreign equity joint venture within China. The total investment and registered capital of the joint venture were both USD 6.88 million, of which Xiamen Hengxing contributed the equivalent of USD 5.16 million in RMB cash, accounting for 75% of the registered capital, and AMOY contributed USD 1.72 million in cash, accounting for 25% of the registered capital. The initial capital contribution from both parties shall not be less than 20% of the registered capital, of which Xiamen Hengxing shall contribute the equivalent of USD 1.032 million in RMB cash, and AMOY shall contribute USD 0.344 million in cash, to be paid in full within 3 months from the date of obtaining the "Business License of Enterprise Legal Person". The remaining contributions shall be paid in full before November 30, 2009. On December 25, 2007, the Xiamen Siming District Investment Affairs Bureau issued the "Approval on the Establishment of Xiamen Aiming Biotechnology Co., Ltd. as a Sino-foreign Equity Joint Venture" (Xia Si Investment Approval [2007] No. 62), approving the establishment of the Sino-foreign equity joint venture Xiamen Aiming Biotechnology Co., Ltd. by Xiamen Hengxing and AMOY and agreeing to the "Sino-foreign Equity Joint Venture Contract" and "Articles of Association" signed by the aforementioned two parties on November 23, 2007. On February 1, 2008, Xiamen Aiming Biotechnology Co., Ltd. held a board meeting and passed a resolution, agreeing to the joint venture.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Forward Investment (Hong Kong) Limited General Legal Person 8770.16 22.51
2 Hong Kong Securities Clearing Company Ltd. Northbound Funds 3538.92 9.08
3 Xiamen Keying Investment Partnership (Limited Partnership) General Legal Person 1594.09 4.09
4 Ningbo Yixiang Self-owned Capital Investment Partnership (Limited Partnership) General Legal Person 873.10 2.24
5 Huabao CSI Medical Care ETF Fund 770.22 1.98
6 Xiamen Haicang District Runding Sheng Investment Partnership (General Partnership) General Legal Person 409.87 1.05
7 National Social Security Fund 413 Portfolio Social Security Fund 311.18 0.80
8 Southern CSI 1000 ETF Fund 250.88 0.64
9 Guoshou Anbao Health Science Hybrid Securities Investment Fund Class A Fund 18.00 0.05
10 CICC CSI 500 Index Enhanced Fund Class A Fund 12.81 0.03

5. Concept Sectors

  • West Coast of the Taiwan Strait
  • Gene Concept
  • Intelligent Healthcare
  • Innovative Drugs
  • Margin Trading & Securities Lending
  • High-Performance Stocks
  • Share Repurchase Plan
  • Pension Funds
  • Specialized, Refined, Differential and Innovative SMEs
  • ChiNext 300
  • ChiNext Blue Chips
  • ChiNext Healthcare
  • ChiNext 200

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information